Notable Labs, Ltd.
NTBLQ Healthcare Biotechnology
Revenue growth for three consecutive years.
Follow NTBLQ
Notable Labs, Ltd. (NTBLQ) EV/Sales
As of 15 October 2026, Notable Labs, Ltd. (NTBLQ) trades at a EV/Sales of 23.3×. Over the past ten years it has ranged from −2,492× (April 2023) to 519× (March 2023); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −686× | — |
| FY2022 | 364× | 251.48% |
| FY2021 | 104× | 76.25% |
| FY2020 | 58.7× | 395.39% |
| FY2019 | 11.9× | — |
| FY2018 | −30.8× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | −10.3× | — |
| Mar 2024 | −70.3× | — |
| Dec 2022 | 364× | — |
| Sep 2022 | −16.3× | — |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. compare | −6.7× |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | 0.0× |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | 4.4× |
| VBIO Valion Bio, Inc. compare | 11.3× |
| NTBLQ Notable Labs, Ltd. | 23.3× |
| WINT Windtree Therapeutics, Inc. compare | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)